Literature DB >> 6109102

Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate.

D F Martin, D Hollanders, S J May, M M Ravenscroft, D E Tweedle, J P Miller.   

Abstract

In a double-blind randomised trial in 75 patients with duodenal ulceration diagnosed endoscopically, 38 patients were given tripotassium dicitrato bismuthate and 37 cimetidine. There was no significant difference in the healing rates between the two drugs after 1 and 2 months, although relief of symptoms was marginally quicker with cimetidine. During follow-up for at least a year, relapse was significantly more common in patients whose ulcers had healed during treatment with cimetidine than in those whose ulcers had healed during treatment with tripotassium dicitrato bismuthate. This difference appears to be related to the medication rather than to any other difference between the two groups of patients. These results suggest that drug treatment given for a short period in duodenal-ulcer disease influences the progress of the disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6109102     DOI: 10.1016/s0140-6736(81)90114-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  56 in total

Review 1.  Presentation and management of Helicobacter pylori infection in childhood.

Authors:  U Blecker; N K Mittal; D I Mehta
Journal:  Indian J Pediatr       Date:  1996 May-Jun       Impact factor: 1.967

Review 2.  Role of Helicobacter pylori in duodenal ulcer.

Authors:  E A Rauws
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

Review 3.  How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.

Authors:  David Y Graham; Sun-Young Lee
Journal:  Gastroenterol Clin North Am       Date:  2015-06-19       Impact factor: 3.806

Review 4.  Helicobacter pylori and peptic ulcers: the present position.

Authors:  S Moss; J Calam
Journal:  Gut       Date:  1992-03       Impact factor: 23.059

Review 5.  Gastric cytoprotection. What does it really mean for the prescriber?

Authors:  M Guslandi
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

6.  Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine.

Authors:  P Sikiric; I Rotkvic; S Mise; M Petek; R Rucman; S Seiwerth; V Zjacic-Rotkvic; M Duvnjak; V Jagic; E Suchanek
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

7.  Gastric ulcer healing with tripotassium dicitrato bismuthate and subsequent relapse.

Authors:  D R Sutton
Journal:  Gut       Date:  1982-07       Impact factor: 23.059

8.  Campylobacter pyloridis in peptic ulcer disease: microbiology, pathology, and scanning electron microscopy.

Authors:  A B Price; J Levi; J M Dolby; P L Dunscombe; A Smith; J Clark; M L Stephenson
Journal:  Gut       Date:  1985-11       Impact factor: 23.059

9.  [Histological and ultrastructural findings in the healing phase of duodenal ulcer].

Authors:  P Malfertheiner; G Bode; U Mader; K Baczako; A Stanescu; H Ditschuneit
Journal:  Klin Wochenschr       Date:  1985-10-15

10.  One week's anti-Helicobacter pylori treatment for duodenal ulcer.

Authors:  R P Logan; P A Gummett; J J Misiewicz; Q N Karim; M M Walker; J H Baron
Journal:  Gut       Date:  1994-01       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.